← All Biorestorative Therapies, INC filings

Biorestorative Therapies, INC 8-K filings

NASDAQ
BRTX
Biorestorative Therapies, INC
8-K: BioRestorative Therapies to Present at 36th Annual ROTH Conference
BioRestorative Therapies will participate in the 36th Annual ROTH Conference, with CEO Lance Alstodt scheduled for a fireside chat.
NASDAQ
BRTX
Biorestorative Therapies, INC
8-K: BioRestorative Therapies Secures $8.1 Million Through Warrant Exercise and New Warrant Issuance
BioRestorative Therapies has raised approximately $8.1 million by incentivizing existing warrant holders to exercise their warrants at a reduced price, while also issuing new warrants.
NASDAQ
BRTX
Biorestorative Therapies, INC
8-K: BioRestorative Therapies Announces Positive Preliminary Phase 2 Data for BRTX-100 in Chronic Lumbar Disc Disease
BioRestorative Therapies released preliminary data from its Phase 2 clinical trial of BRTX-100, showing positive trends in pain and function for patients with chronic lumbar disc disease.
NASDAQ
BRTX
Biorestorative Therapies, INC
8-K: BioRestorative Therapies to Present Preliminary Data on BRTX-100 at Orthopaedic Research Society Meeting
BioRestorative Therapies will present preliminary 26-week blinded data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease at the Orthopaedic Research Society 2024 Annual Meeting.